BPC-157 vs TB-500

Overview

This comparison separates BPC-157 and TB-500 for reference—not product selection.

BPC-157: Synthetic gastric peptide widely studied in animal tissue-repair models, with very limited human data.

TB-500: Synthetic fragment of thymosin beta-4 studied in cell migration and tissue repair research.

Differences

• BPC-157 literature emphasises GI cytoprotection, angiogenesis, and localized repair models.
• TB-500 literature emphasises actin-related cell migration and thymosin β4 fragment biology.

Mechanism

BPC-157: The mechanism most consistently reported is an effect on new blood vessel formation, called angiogenesis. Healing tissue needs a blood supply, and BPC-157 appea…

TB-500: Actin is the protein cells use to change shape and move. Thymosin beta-4 binds actin and controls how readily it assembles, which in turn affects how quickly ce…

Pharmacology

BPC-157: Pharmacokinetic detail should be read from primary literature.

TB-500: Pharmacokinetic detail should be read from primary literature.

Research

BPC-157: Tissue repair & recovery research: Accelerated tendon-to-bone healing with improved biomechanical properties; most effective with localized injection.

TB-500: Tissue repair & recovery research: Accelerated healing of muscle fibers with reduced recovery time and enhanced repair via cell migration and differentiation.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/39325560/
• pubmed.ncbi.nlm.nih.gov/32334036/
• pubmed.ncbi.nlm.nih.gov/40131143/
• pubmed.ncbi.nlm.nih.gov/27847966/
• pubmed.ncbi.nlm.nih.gov/14554208/
• pubmed.ncbi.nlm.nih.gov/32445447/
• pubmed.ncbi.nlm.nih.gov/31266512/
• pubmed.ncbi.nlm.nih.gov/16609979/

Questions